New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies

BioDrugs

Volumn 25, Issue 1, 2011, Pages 13-25

  Robak, Tadeusz ^a,b   Robak, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Anti CD20 monoclonal antibody, general; B cell modulators, general; CD20 antigen inhibitors, general; Lymphoid leukaemia; Lymphoma; Lymphoproliferative disorders; Monoclonal antibodies, general; Research and development.

Indexed keywords

AME 133 V; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FLUDARABINE; HA 20; LY 2469298; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PRO 131921; RITUXIMAB; RO 5072759; TRU 015; UNCLASSIFIED DRUG; VELTUZUMAB;

ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AREA UNDER THE CURVE; B CELL LYMPHOMA; BLOOD TOXICITY; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FEVER; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIARTHRITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, B-CELL; TREATMENT OUTCOME;

EID: 78651376557     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11539590-000000000-00000     Document Type: Review

References (88)

1. Cragg MS, Walshe CA, Ivanov AO, et al. The biology ofCD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-74
2. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple trans-membrane domains. EMBO J 1988; 7: 711-7
3. Stashenko P, Nadler L M, Hardy R, et al. Expressionofcell surfacemarkers after human B lymphocyte activation. Proc Natl Acad Sci USA 1981; 78: 3848-52
4. Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47: 107-14
5. Li H, Ayer LM, Lytton J, et al. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003; 278: 42427-34
6. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy ofanti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-201
7. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 2003; 123: 850-7
8. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101 (7): 2507-13
9. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444-9
10. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659-69
11. Lefebvre ML, Krause SW, Salcedo M, et al. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rit-uximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006; 29: 388-97
12. Boye J, Elter T, Engert A. An overview of the current clinical use of the antiCD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520-35
13. Robak T, Dmoszynska A, Solal-Celigny A, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lym-phocytic leukemia. J Clin Oncol 2010; 28: 1756-65
14. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 2009; 69: 2415-49
15. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58: 79-88
16. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-8
17. Zhou X, Hu W, Qin X. The role of complement in themechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13: 954-66
18. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evi-dence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-43
19. Pedersen IM, Buhl AM, Klausen P, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99: 1314-9
20. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Im-munol 2006; 177: 362-71
21. Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol 2000; 27 Suppl. 12: 30-6
22. Stolz C, Schuler M. Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009; 50: 873-85
23. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in Ig G Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-8
24. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concen-tration-effect relationship. Cancer Res 2004; 64: 4664-9
25. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among in-dividuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 2007; 110: 2561-4
26. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108: 2720-5
27. Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14: 6697-703
28. van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12: 4027-35
29. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-9
30. Weitzman J, Betancur M, Boissel L, et al. Variable contribution ofmonoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 1361-8
31. Henry C, Deschamps M, Rohrlich PS, et al. Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood 2010; 115: 2420-9
32. Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versuslymphoma effects. In: Hematology. Washington, DC: American Society of Hematology, 2007: 226-32
33. Robak T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chem 2009; 16: 2212-34
34. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther 2008; 10: 294-309
35. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95: 135-43
36. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, et al. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3: 1157-71
37. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008; 9: 1206-15
38. Robak T. GA-101, a third-generation, humanized and glyco-engineered antiCD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009; 10: 588-96
39. van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010; 47: 199-210
40. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112: 4170-7
41. Hammadi M, Pers JO, Berthou C, et al. A new approach to comparing antiCD20 antibodies: importance of the lipid rafts in their lytic efficiency. Onco Targets Ther 2010; 3: 99-109
42. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111: 1094-100
43. Coiffier B, Losic N, Rønn BB, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with elapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol 2010; 150: 58-71
44. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-55
45. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 2008; 111: 5486-95
46. Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 935
47. Salles GA, Morschhauser F, Cartron G, et al. A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease [ab-stract]. Blood (ASH Annual Meeting Abstracts) 2008; 93: 234
48. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 884
49. Salles G, Morschhauser F, Lamy T, et al. Phase Istudy of RO5072759(GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 1704
50. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009; 27: 3346-53
51. Negrea OG, Allen SL, Rai KR, et al. Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malig-nancies [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3757
52. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with rela-psed/refractory follicular lymphoma. Ann Oncol 2010; 21: 1870-6
53. + indolent NHL: correlation between clinical responses and AUC pharmaco-kinetics [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3742
54. Robak T. Ofatumumab for the treatment of chronic lymphocytic leukemia. Therapy 2009; 6: 577-87
55. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181:822-32
56. Du J, Yang H, Guo Y, et al. Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009; 46: 2419-23
57. Teeling JL, French RR, Cragg MS, et al. Characterization ofnew human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793-800
58. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment ofB-cell malignancies. J Clin Oncol 2010; 28: 3525-30
59. Taylor RP, Beum PV, Stukenberg TP, et al. Complement (C) activation followed by penetration of the membrane attack complex (MAC) on B cells opsonized with CD20 mabs allows for calcium influx which induces stream-ers: generalization of streaming to include other mabs and target cells [ab-stract]. Blood (ASH Annual Meeting Abstracts) 2008; 112: 1577
60. Wierda WG, Kipps TJ, Durig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 207
61. Robak T, Osterborg A, Kipps TJ, et al. High response rats and clinical improvements with single-agent ofatumumab in fludarabine: refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy [abstract 9.7]. Haematologica 2009; 94 Suppl. 3: 81
62. Wierda WG, Ronn BB, Jewell RC, et al. Circulating ofatumumab concentrations correlate with response and progression-free survivalin fludarabinerefractory chronic lymphocytic leukemia [abstract 10.28]. Haematologica 2009; 94 Suppl. 3: 92
63. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment ofnonHodgkin's lymphoma, chronic lymphocytic leukemia and immune throm-bocytopenic purpura. Curr Opin Mol Ther 2009; 11: 200-7
64. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113: 1062-70
65. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the hu-manized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodg-kin's lymphoma. Clin Cancer Res 2004; 10: 2868-78
66. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010; 51: 747-55
67. Kausar F, Mustafa K, Sweis G, et al. Ocrelizumab: a step forward in the evolution ofB-cell therapy. Expert Opin Biol Ther 2009; 9: 889-95
68. Genovese MC, Kaine JL, Lowenstein MB, et al., ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 2652-61
69. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008; 8: 156-71
70. Martin P, Furman RR, Ruan J, et al. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol 2008; 45: 126-32
71. Campbell BJ, Barrett AMA, Ondek MD, et al. AME-133: A next-generation anti-CD20 engineered for enhanced killer function [abstract]. J Immunother 2004; 27: 52
72. Bowles JA, Wang SY, Link BK et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108: 2648-54
73. Bello C, Eduardo M. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. In: Hematology. Washington, DC: American Society of Hem-atology, 2007: 233-42
74. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-23
75. Safety and efficacy study of an anti-CD20 monoclonal antibody (AME-133v) to treat non-Hodgkin's lymphoma [online]. Available from URL: http://Clinical Trials.gov [Accessed 2009 Jun 3]
76. Umana P, Moessner E, Bruenker P, et al. Novel3rd generation humanized type II CD20 antibody with glycoengineered Fc and fodified elbow hinge for en-hanced ADCC and superior apoptosis induction [abstract]. Blood (ASH Annual Meeting Abstracts) 2006; 108: 22
77. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy ofCD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-402
78. Umana P, Ekkehard M, Peter B, et al. GA101, anovelhumanizedtypeIICD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo [ab-stract]. Blood (ASH Annual Meeting Abstracts) 2007; 110: 2348
79. Friess T, Gerdes C, Nopora A, et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, medi-ates superior efficacy in a variety of NHL xenograft models in comparison to rituximab [abstract]. Blood (ASH Annual Meeting Abstracts) 2007; 110: 2338
80. Niederfellner GJ, Lammens A, Schwaiger M, et al. Crystal structure analysis reveals that the novel type II anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3726
81. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 Ig G fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 2009; 10: 1383-90
82. Hayden-Ledbetter M, Magaletti D, Mohler K, et al. CD16-mediated antibody dependent cellular cytotoxicity is required for B cell depletion by a small modular Immuno Pharmaceutical specific for CD20 [abstract]. Blood (ASH Annual Meeting Abstracts) 2003; 102: 2388
83. Barone D, Burge DJ, Baum P, et al. Prolonged depletion ofcirculatingB cells in cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic. Ann Rheum Dis 2005; 64 Suppl. 3: 159-60
84. Burge D, Martin R, Wallace D, et al. Safety and pharmacodynamics of repeat administration of TRU-015, a CD20-directed SMIP(TM) therapeutic, in sub-jects with rheumatoid arthritis. Arthritis Rheum 2007; 56 (9 Suppl.): S168-9
85. Barone D. TRU-015, a novel CD20-directed biologic therapy, demonstrates significant anti-tumor activity in human tumor xenograft models [abstract]. Proc Am Soc Clin Oncol 2005; 24: 2549
86. Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 2009; 15: 2739-46
87. Rubbert-Roth A. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis. Curr Opin Mol Ther 2010; 12: 115-23
88. Burge DJ, Bookbinder SA, Kivitz AJ, et al. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immuno-pharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a phase I, open-label, dose-escalation clinical study. Clin Ther 2008; 30: 1806-16